Cue Biopharma Inc Ordinary Shares CUE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)
-
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
-
Cue Biopharma Names James Ahlers CFO
-
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission
Trading Information
- Previous Close Price
- $18.45
- Day Range
- $17.74–18.82
- 52-Week Range
- $4.97–45.50
- Bid/Ask
- $16.50 / $18.86
- Shares Outstanding
- 7.26M
- Market Cap
- $133.08M
- Volume/Avg
- 7 / 267,585
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 29
- Website
- https://www.cuebiopharma.com
Valuation
|
Metric
|
CUE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 41.47 |
Price/Sales | 2.20 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CUE
|
|---|---|
Quick Ratio | 1.16 |
Current Ratio | 1.25 |
Interest Coverage | −1,216.21 |
Quick Ratio
CUE
Profitability
|
Metric
|
CUE
|
|---|---|
Return on Assets (Normalized) | −391.88% |
Return on Equity (Normalized) | −844.34% |
Return on Invested Capital (Normalized) | −652.26% |
Return on Assets
CUE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>cjB$Q! | LOCK|$RlYG | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|l$P>Zj | LOCK|kZssV | $84B | |||
| Moderna Inc
MRNA
| LOCK|M&s>gQF | LOCK|Jw^ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|s>Hr%?j | LOCK|vZv | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|xWlRfZG | LOCK|Ng | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^#nW<%M | LOCK|!QP^ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?>BJdD^ | LOCK|>DFv? | $29B | |||
| Incyte Corp
INCY
| LOCK|ZD@DP@? | LOCK|Y? | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|F^ZXw&K | LOCK|$<B | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|&yH&!?! | LOCK|pF | $14B |
United States